Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 4, 1999, Pages 309-315

  Reigner, Bruno ^a   Clive, Sally ^b   Cassidy, Jim ^c   Jodrell, Duncan ^b   Schulz, Rainer ^d   Goggin, Timothy ^a   Banken, Ludger ^a   Roos, Brigitte ^a   Utoh, Masahiro ^e   Mulligan, Thomas ^f   Weidekamm, Erhard ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b NHS LOTHIAN   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d Roche Clinical Pharmacology Unit   (France)

^e NIPPON ROCHE RESEARCH CENTER   (Japan)

^f HOFFMANN LA ROCHE INC   (United States)

Author keywords

5 Fluorouracil; Capecitabine; Maalox; Pharmacokinetic interaction

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; CAPECITABINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; ALUMINUM HYDROXIDE; ANTACIDS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CROSS-OVER STUDIES; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; HALF-LIFE; HUMANS; MAGNESIUM HYDROXIDE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS;

EID: 0032979671     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050900     Document Type: Article

References (11)

1. 1. Findlay M, Van Cutsem E, Kocha W, Allman D, Laffranchi B, Griffin T, Osterwalder B, Dalley D, Pazdur R, Verweij J (1997) A randomized phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer (abstract 798). Proc Am Soc Clin Oncol 16: 227A
2. 2. Blum JL, Buzdur AU, Lo Russo PM, et al (1998) A multicenter phase II trial of Xeloda (capecitabine) in Paclitaxel-refractory metastatic breast cancer (abstract 476). Proc Am Soc Clin Oncol 17: 125
3. 3. Takebayashi Y, Akiyama S, Akiba S, et al (1996) Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88: 1110-1117
4. 4. Schueller J, Cassidy J, Reigner B, Durston S, Roos B, Ishitsuka H, Utoh M, Dumont E (1997) Tumor selectivity of Xeloda in colorectal cancer patients (abstract). Proc Am Soc Clin Oncol 16: 227
5. 5. Diasio RB, Harris BE (1990) Clinical pharmacology of 5-fluorouracil. Pharmacokinetics 16: 215-237
6. 6. Janknegt D (1990) Drug interactions with quinolones. J Antimicrob Chemother 26 [Suppl D]: 7-29
7. 7. Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A (1990) Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother 34: 432-435
8. 8. Harcourt RS, Hamburger M (1957) The effect of magnesium sulfate in lowering tetracycline blood levels. J Lab Clin Med 50: 464-468
9. 9. Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M, Osterwalder B (1998) Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 4: 941-948
10. 10. Gibaldi M, Perrier D (1992) Pharmacokinetics, 2nd ed. Marcel Dekker, New York
11. 11. Arnold LA, Spurbeck GH, Shelver WH, Henderson WM (1979) Effect of an antacid on gastrointestinal absorption of theophylline. Am J Hosp Pharm 36: 1059-1062